Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Phase 1 Completed 35 enrolled Akeso

NaSingle-groupOpen-labelTreatment

Summary

Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.

Timeline

Start: 2021-03-29
Primary completion: 2023-12-04
Completion: 2023-12-04

Publications

Chen Z, Wu L, Wang Q, Yu Y, Liu X, Ma R, Li T, Li Y, Song X, Li L, Zhao W, Wang Q, Xu X, Lu S. Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial. J Thorac Oncol. 2025 Feb;20(2):233-239. doi: 10.1016/j.jtho.2024.10.013. Epub 2024 Oct 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivonescimab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Ivonescimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Ivonescimab	Monoclonal antibody	20 mg/kg	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Etoposide	Small molecule	100 mg/m2	Intravenous

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Summary

Timeline

Publications

Drugs

Indications